Download PDF
Digestive Disease Interventions 2017; 01(02): 066-073
DOI: 10.1055/s-0037-1603572
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis

Hafiz Muhammad Sharjeel Arshad
1   Department of Internal Medicine, University of Illinois at Chicago, Advocate Christ Medical Center, Champaign, Illinois
,
Sean Koppe
2   Division of Gastroenterology and Hepatology, Department of Medicine, University of Illinois at Chicago, Champaign, Illinois
› Author Affiliations
Further Information

Publication History

22 February 2017

25 April 2017

Publication Date:
01 June 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease in the United States. Approximately 10 to 20% of patients with NAFLD progress to nonalcoholic steatohepatitis (NASH). NASH can progress to cirrhosis, which, in turn, can lead to hepatocellular carcinoma (HCC). However, evidence also supports that HCC can develop in patients with NASH who do not have cirrhosis or advanced fibrosis. Obesity, diabetes mellitus, hepatic iron deposition, and insulin resistance are potential risk factors for HCC in NASH. Mechanisms proposed include a role for tumor necrosis factor-α, interleukin-6, insulinlike growth factor, and nuclear factor κβ activation in progression of NASH to HCC. Polymorphisms in patatin-like phospholipase domain-containing 3 also support a genetic influence in NASH-related HCC. Surgical resection, liver directed therapy, and liver transplant remain the mainstay of therapy. Ultrasound has reduced sensitivity for surveillance of HCC in obese patients and alpha fetoprotein may have more value for HCC surveillance in the NASH patient as compared with the HCV patient. Although HCC can develop in noncirrhotic NASH, currently there are no guidelines to recommend surveillance in noncirrhotic NASH patients.

Keywords

nonalcoholic fatty liver disease - nonalcoholic steatohepatitis - fatty liver disease - hepatocellular carcinoma
 

  • References

  • 1 World Health Organization. Mortality database. Available at www.who.int/whosis/en . Accessed February 2010
    PubMedGoogle Scholar
  • 2 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61 (02) 69-90
    CrossrefPubMedGoogle Scholar
  • 3 El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132 (07) 2557-2576
    CrossrefPubMedGoogle Scholar
  • 4 Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol 2014; 109 (04) 542-553
    CrossrefPubMedGoogle Scholar
  • 5 Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology 2015; 61 (01) 191-199
    CrossrefPubMedGoogle Scholar
  • 6 Williams CD, Stengel J, Asike MI. , et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140 (01) 124-131
    CrossrefPubMedGoogle Scholar
  • 7 Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007; 11 (01) 1-16 , vii
    CrossrefPubMedGoogle Scholar
  • 8 Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 2007; 11 (01) 191-207 , x–xi
    CrossrefPubMedGoogle Scholar
  • 9 Kawada N, Imanaka K, Kawaguchi T. , et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 2009; 44 (12) 1190-1194
    CrossrefPubMedGoogle Scholar
  • 10 Perumpail RB, Wong RJ, Ahmed A, Harrison SA. Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver disease and the metabolic syndrome: US experience. Dig Dis Sci 2015; 60 (10) 3142-3148
    CrossrefPubMedGoogle Scholar
  • 11 Browning JD, Szczepaniak LS, Dobbins R. , et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40 (06) 1387-1395
    CrossrefPubMedGoogle Scholar
  • 12 Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98 (05) 960-967
    CrossrefPubMedGoogle Scholar
  • 13 Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005; 50 (01) 171-180
    CrossrefPubMedGoogle Scholar
  • 14 Shen L, Fan JG, Shao Y. , et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 2003; 9 (05) 1106-1110
    CrossrefPubMedGoogle Scholar
  • 15 Omagari K, Kadokawa Y, Masuda J. , et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 2002; 17 (10) 1098-1105
    CrossrefPubMedGoogle Scholar
  • 16 Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27 (02) 142-149
    CrossrefPubMedGoogle Scholar
  • 17 Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a ‘normal’ population--examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977; 12 (05) 593-597
    CrossrefPubMedGoogle Scholar
  • 18 Lai SW, Tan CK, Ng KC. Epidemiology of fatty liver in a hospital-based study in Taiwan. South Med J 2002; 95 (11) 1288-1292
    CrossrefPubMedGoogle Scholar
  • 19 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease - meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64 (01) 73-84
    CrossrefPubMedGoogle Scholar
  • 20 Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999; 94 (10) 3010-3014
    CrossrefPubMedGoogle Scholar
  • 21 Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001; 35 (02) 195-199
    CrossrefPubMedGoogle Scholar
  • 22 Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009; 115 (24) 5651-5661
    CrossrefPubMedGoogle Scholar
  • 23 Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42 (01) 132-138
    PubMedGoogle Scholar
  • 24 Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003; 98 (09) 2042-2047
    CrossrefPubMedGoogle Scholar
  • 25 Pais R, Charlotte F, Fedchuk L. , et al; LIDO Study Group. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 2013; 59 (03) 550-556
    CrossrefPubMedGoogle Scholar
  • 26 Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116 (06) 1413-1419
    CrossrefPubMedGoogle Scholar
  • 27 Fassio E, Alvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004; 40 (04) 820-826
    PubMedGoogle Scholar
  • 28 Kodali VP, Gordon SC, Silverman AL, McCray DG. Cryptogenic liver disease in the United States: further evidence for non-A, non-B, and non-C hepatitis. Am J Gastroenterol 1994; 89 (10) 1836-1839
    PubMedGoogle Scholar
  • 29 Saunders JB, Walters JR, Davies AP, Paton A. A 20-year prospective study of cirrhosis. Br Med J (Clin Res Ed) 1981; 282 (6260): 263-266
    CrossrefPubMedGoogle Scholar
  • 30 Sakugawa H, Nakasone H, Nakayoshi T. , et al. Clinical characteristics of patients with cryptogenic liver cirrhosis in Okinawa, Japan. Hepatogastroenterology 2003; 50 (54) 2005-2008
    PubMedGoogle Scholar
  • 31 Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29 (03) 664-669
    CrossrefPubMedGoogle Scholar
  • 32 Bugianesi E, Leone N, Vanni E. , et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123 (01) 134-140
    CrossrefPubMedGoogle Scholar
  • 33 Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 1995; 20 (02) 127-130
    CrossrefPubMedGoogle Scholar
  • 34 Ong J, Younossi ZM, Reddy V. , et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001; 7 (09) 797-801
    CrossrefPubMedGoogle Scholar
  • 35 Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004; 2 (12) 1048-1058
    CrossrefPubMedGoogle Scholar
  • 36 Garcìa-Torres ML, Zaragoza A, Giner R. , et al. Incidencia y factores epidemiol Ûgicos del carcinoma hepatocelular en Valencia durante el año 2000. Rev Esp Enferm Dig 2003; 95: 381-384
    PubMedGoogle Scholar
  • 37 Cotrim HP, Paraná R, Braga E, Lyra L. Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history?. Am J Gastroenterol 2000; 95 (10) 3018-3019
    CrossrefPubMedGoogle Scholar
  • 38 Zen Y, Katayanagi K, Tsuneyama K, Harada K, Araki I, Nakanuma Y. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 2001; 51 (02) 127-131
    CrossrefPubMedGoogle Scholar
  • 39 Orikasa H, Ohyama R, Tsuka N, Eyden BP, Yamazaki K. Lipid-rich clear-cell hepatocellular carcinoma arising in non-alcoholic steatohepatitis in a patient with diabetes mellitus. J Submicrosc Cytol Pathol 2001; 33 (1-2): 195-200
    PubMedGoogle Scholar
  • 40 Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36 (06) 1349-1354
    CrossrefPubMedGoogle Scholar
  • 41 Ratziu V, Bonyhay L, Di Martino V. , et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35 (06) 1485-1493
    CrossrefPubMedGoogle Scholar
  • 42 Giannini EG, Marabotto E, Savarino V. , et al; Italian Liver Cancer (ITALICA) Group. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. Clin Gastroenterol Hepatol 2009; 7 (05) 580-585
    CrossrefPubMedGoogle Scholar
  • 43 Lee SS, Jeong SH, Byoun YS. , et al. Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma. BMC Cancer 2013; 13: 335
    CrossrefPubMedGoogle Scholar
  • 44 White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012; 10 (12) 1342-1359.e2
    CrossrefPubMedGoogle Scholar
  • 45 Yasui K, Hashimoto E, Komorizono Y. , et al; Japan NASH Study Group, Ministry of Health, Labour, and Welfare of Japan. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9 (05) 428-433 , quiz e50
    CrossrefPubMedGoogle Scholar
  • 46 Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?. Arch Pathol Lab Med 2008; 132 (11) 1761-1766
    PubMedGoogle Scholar
  • 47 Leung C, Yeoh SW, Patrick D. , et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol 2015; 21 (04) 1189-1196
    CrossrefPubMedGoogle Scholar
  • 48 Mittal S, El-Serag HB, Sada YH. , et al. Hepatocellular carcinoma in the absence of cirrhosis in United States Veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2016; 14 (01) 124-31.e1
    CrossrefPubMedGoogle Scholar
  • 49 Alexander J, Torbenson M, Wu TT, Yeh MM. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study. J Gastroenterol Hepatol 2013; 28 (05) 848-854
    CrossrefPubMedGoogle Scholar
  • 50 Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55 (07) 434-438
    PubMedGoogle Scholar
  • 51 Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989; 20 (06) 594-598
    CrossrefPubMedGoogle Scholar
  • 52 Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome?. Clin Nutr 1999; 18 (06) 353-358
    CrossrefPubMedGoogle Scholar
  • 53 Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?. Hepatology 2002; 36 (01) 150-155
    PubMedGoogle Scholar
  • 54 Wolk A, Gridley G, Svensson M. , et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001; 12 (01) 13-21
    CrossrefPubMedGoogle Scholar
  • 55 Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348 (17) 1625-1638
    CrossrefPubMedGoogle Scholar
  • 56 Møller H, Mellemgaard A, Lindvig K, Olsen JH. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994; 30A (03) 344-350
    PubMedGoogle Scholar
  • 57 Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 2005; 23 (21) 4742-4754
    CrossrefPubMedGoogle Scholar
  • 58 Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 2007; 97 (07) 1005-1008
    CrossrefPubMedGoogle Scholar
  • 59 Chen CL, Yang HI, Yang WS. , et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135 (01) 111-121
    CrossrefPubMedGoogle Scholar
  • 60 Stefan N, Häring HU. The metabolically benign and malignant fatty liver. Diabetes 2011; 60 (08) 2011-2017
    CrossrefPubMedGoogle Scholar
  • 61 Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54 (04) 533-539
    CrossrefPubMedGoogle Scholar
  • 62 La Vecchia C, Negri E, D'Avanzo B, Boyle P, Franceschi S. Medical history and primary liver cancer. Cancer Res 1990; 50 (19) 6274-6277
    PubMedGoogle Scholar
  • 63 Adami HO, McLaughlin J, Ekbom A. , et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991; 2 (05) 307-314
    CrossrefPubMedGoogle Scholar
  • 64 Yu MC, Tong MJ, Govindarajan S, Henderson BE. Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst 1991; 83 (24) 1820-1826
    CrossrefPubMedGoogle Scholar
  • 65 Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami HO. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 2000; 92 (13) 1096-1099
    CrossrefPubMedGoogle Scholar
  • 66 El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126 (02) 460-468
    CrossrefPubMedGoogle Scholar
  • 67 El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4 (03) 369-380
    CrossrefPubMedGoogle Scholar
  • 68 Mendler MH, Turlin B, Moirand R. , et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117 (05) 1155-1163
    CrossrefPubMedGoogle Scholar
  • 69 Bozzini C, Girelli D, Olivieri O. , et al. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 2005; 28 (08) 2061-2063
    CrossrefPubMedGoogle Scholar
  • 70 Felipe A, Guadalupe E, Druso P. , et al. Serum ferritin is associated with metabolic syndrome and red meat consumption. Oxid Med Cell Longev 2015; 2015: 769-735
    PubMedGoogle Scholar
  • 71 George DK, Goldwurm S, MacDonald GA. , et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114 (02) 311-318
    CrossrefPubMedGoogle Scholar
  • 72 Bugianesi E, Manzini P, D'Antico S. , et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004; 39 (01) 179-187
    CrossrefPubMedGoogle Scholar
  • 73 Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A, Vecchione R. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol 2009; 50 (02) 351-357
    CrossrefPubMedGoogle Scholar
  • 74 Svegliati-Baroni G, Bugianesi E, Bouserhal T. , et al. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease. Gut 2007; 56 (09) 1296-1301
    CrossrefPubMedGoogle Scholar
  • 75 De Minicis S, Agostinelli L, Rychlicki C. , et al. HCC development is associated to peripheral insulin resistance in a mouse model of NASH. PLoS One 2014; 9 (05) e97136
    CrossrefPubMedGoogle Scholar
  • 76 Levene AP, Goldin RD. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 2012; 61 (02) 141-152
    PubMedGoogle Scholar
  • 77 Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci 2013; 14 (10) 20704-20728
    CrossrefPubMedGoogle Scholar
  • 78 Hashimoto E, Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: growing evidence of an epidemic?. Hepatol Res 2012; 42 (01) 1-14
    CrossrefPubMedGoogle Scholar
  • 79 Castell JV, Gómez-Lechón MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990; 12 (05) 1179-1186
    CrossrefPubMedGoogle Scholar
  • 80 Park EJ, Lee JH, Yu GY. , et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140 (02) 197-208
    CrossrefPubMedGoogle Scholar
  • 81 Wang Y, Ausman LM, Greenberg AS, Russell RM, Wang XD. Nonalcoholic steatohepatitis induced by a high-fat diet promotes diethylnitrosamine-initiated early hepatocarcinogenesis in rats. Int J Cancer 2009; 124 (03) 540-546
    CrossrefPubMedGoogle Scholar
  • 82 Bettermann K, Vucur M, Haybaeck J. , et al. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell 2010; 17 (05) 481-496
    CrossrefPubMedGoogle Scholar
  • 83 Solinas G, Naugler W, Galimi F, Lee MS, Karin M. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc Natl Acad Sci U S A 2006; 103 (44) 16454-16459
    CrossrefPubMedGoogle Scholar
  • 84 Wang XJ, Yuan SL, Lu Q. , et al. Potential involvement of leptin in carcinogenesis of hepatocellular carcinoma. World J Gastroenterol 2004; 10 (17) 2478-2481
    CrossrefPubMedGoogle Scholar
  • 85 Watanabe N, Takai K, Imai K. , et al. Increased levels of serum leptin are a risk factor for the recurrence of stage I/II hepatocellular carcinoma after curative treatment. J Clin Biochem Nutr 2011; 49 (03) 153-158
    CrossrefPubMedGoogle Scholar
  • 86 Kamada Y, Matsumoto H, Tamura S. , et al. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 2007; 47 (04) 556-564
    CrossrefPubMedGoogle Scholar
  • 87 Saxena NK, Fu PP, Nagalingam A. , et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology 2010; 139 (05) 1762-1773 , 1773.e1–1773.e5
    CrossrefPubMedGoogle Scholar
  • 88 Price JA, Kovach SJ, Johnson T. , et al. Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma. Hepatology 2002; 36 (05) 1089-1097
    CrossrefPubMedGoogle Scholar
  • 89 Aleem E, Nehrbass D, Klimek F, Mayer D, Bannasch P. Upregulation of the insulin receptor and type I insulin-like growth factor receptor are early events in hepatocarcinogenesis. Toxicol Pathol 2011; 39 (03) 524-543
    CrossrefPubMedGoogle Scholar
  • 90 Longato L, de la Monte S, Kuzushita N. , et al. Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology 2009; 49 (06) 1935-1943
    CrossrefPubMedGoogle Scholar
  • 91 Chiang SH, Bazuine M, Lumeng CN. , et al. The protein kinase IKKepsilon regulates energy balance in obese mice. Cell 2009; 138 (05) 961-975
    CrossrefPubMedGoogle Scholar
  • 92 Feldstein AE, Werneburg NW, Canbay A. , et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004; 40 (01) 185-194
    CrossrefPubMedGoogle Scholar
  • 93 Luedde T, Schwabe RF. NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011; 8 (02) 108-118
    CrossrefPubMedGoogle Scholar
  • 94 Sass G, Klinger N, Sirma H. , et al. Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT. Int J Oncol 2011; 39 (02) 433-442
    PubMedGoogle Scholar
  • 95 Maeda S. NF-κB, JNK, and TLR signaling pathways in hepatocarcinogenesis. Gastroenterol Res Pract 2010; 2010: 367694
    PubMedGoogle Scholar
  • 96 Chang Q, Zhang Y, Beezhold KJ. , et al. Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. J Hepatol 2009; 50 (02) 323-333
    CrossrefPubMedGoogle Scholar
  • 97 Eferl R, Ricci R, Kenner L. , et al. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 2003; 112 (02) 181-192
    CrossrefPubMedGoogle Scholar
  • 98 Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 2009; 41 (09) 615-625
    CrossrefPubMedGoogle Scholar
  • 99 Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001; 96 (10) 2957-2961
    CrossrefPubMedGoogle Scholar
  • 100 Makkonen J, Pietiläinen KH, Rissanen A, Kaprio J, Yki-Järvinen H. Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins. J Hepatol 2009; 50 (05) 1035-1042
    CrossrefPubMedGoogle Scholar
  • 101 Bathum L, Petersen HC, Rosholm JU, Hyltoft Petersen P, Vaupel J, Christensen K. Evidence for a substantial genetic influence on biochemical liver function tests: results from a population-based Danish twin study. Clin Chem 2001; 47 (01) 81-87
    CrossrefPubMedGoogle Scholar
  • 102 Dixon JB, Bhathal PS, Jonsson JR, Dixon AF, Powell EE, O'Brien PE. Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol 2003; 39 (06) 967-971
    CrossrefPubMedGoogle Scholar
  • 103 Romeo S, Kozlitina J, Xing C. , et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40 (12) 1461-1465
    CrossrefPubMedGoogle Scholar
  • 104 Valenti L, Al-Serri A, Daly AK. , et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51 (04) 1209-1217
    CrossrefPubMedGoogle Scholar
  • 105 Hassan MM, Kaseb A, Etzel CJ. , et al. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog 2013; 52 (Suppl. 01) E139-E147
    CrossrefPubMedGoogle Scholar
  • 106 Speliotes EK, Yerges-Armstrong LM, Wu J. , et al; NASH CRN; GIANT Consortium; MAGIC Investigators; GOLD Consortium. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7 (03) e1001324
    CrossrefPubMedGoogle Scholar
  • 107 Yoneda M, Hotta K, Nozaki Y. , et al. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver Int 2009; 29 (07) 1078-1085
    CrossrefPubMedGoogle Scholar
  • 108 Sreenivasa Baba C, Alexander G, Kalyani B. , et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2006; 21 (1 Pt 1): 191-198
    CrossrefPubMedGoogle Scholar
  • 109 Hickman IJ, Jonsson JR, Prins JB. , et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53 (03) 413-419
    CrossrefPubMedGoogle Scholar
  • 110 Lazo M, Solga SF, Horska A. , et al; Fatty Liver Subgroup of the Look AHEAD Research Group. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010; 33 (10) 2156-2163
    CrossrefPubMedGoogle Scholar
  • 111 Kirk E, Reeds DN, Finck BN, Mayurranjan SM, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009; 136 (05) 1552-1560
    CrossrefPubMedGoogle Scholar
  • 112 Wang RT, Koretz RL, Yee Jr HF. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med 2003; 115 (07) 554-559
    CrossrefPubMedGoogle Scholar
  • 113 Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358 (9285): 893-894
    CrossrefPubMedGoogle Scholar
  • 114 Uygun A, Kadayifci A, Isik AT. , et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19 (05) 537-544
    CrossrefPubMedGoogle Scholar
  • 115 Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34 (03) 274-285
    CrossrefPubMedGoogle Scholar
  • 116 Aithal GP, Thomas JA, Kaye PV. , et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135 (04) 1176-1184
    CrossrefPubMedGoogle Scholar
  • 117 Sanyal AJ, Chalasani N, Kowdley KV. , et al; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362 (18) 1675-1685
    CrossrefPubMedGoogle Scholar
  • 118 Laurin J, Lindor KD, Crippin JS. , et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23 (06) 1464-1467
    CrossrefPubMedGoogle Scholar
  • 119 Leuschner UF, Lindenthal B, Herrmann G. , et al; NASH Study Group. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52 (02) 472-479
    CrossrefPubMedGoogle Scholar
  • 120 Horlander JC, Kwo PY, Cummings OW. , et al. Atorvastatin for the treatment of NASH. Gastroenterology 2001; 120 (Suppl): 2767
    PubMedGoogle Scholar
  • 121 Gómez-Domínguez E, Gisbert JP, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006; 23 (11) 1643-1647
    CrossrefPubMedGoogle Scholar
  • 122 Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ 2016; 352: i1541
    PubMedGoogle Scholar
  • 123 Riche DM, King ST. Bone loss and fracture risk associated with thiazolidinedione therapy. Pharmacotherapy 2010; 30 (07) 716-727
    CrossrefPubMedGoogle Scholar
  • 124 Klein EA, Thompson Jr IM, Tangen CM. , et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306 (14) 1549-1556
    CrossrefPubMedGoogle Scholar
  • 125 Chen HP, Shieh JJ, Chang CC. , et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 2013; 62 (04) 606-615
    CrossrefPubMedGoogle Scholar
  • 126 Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008; 6 (12) 1396-1402
    CrossrefPubMedGoogle Scholar
  • 127 Malik SM, Gupte PA, de Vera ME, Ahmad J. Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clin Gastroenterol Hepatol 2009; 7 (07) 800-806
    CrossrefPubMedGoogle Scholar
  • 128 Reddy SK, Steel JL, Chen HW. , et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 2012; 55 (06) 1809-1819
    CrossrefPubMedGoogle Scholar
  • 129 Wong RJ, Chou C, Bonham CA, Concepcion W, Esquivel CO, Ahmed A. Improved survival outcomes in patients with non-alcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002-2012 United Network for Organ Sharing data. Clin Transplant 2014; 28 (06) 713-721
    CrossrefPubMedGoogle Scholar
  • 130 Bruix J, Sherman M. ; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (03) 1020-1022
    CrossrefPubMedGoogle Scholar
  • 131 Del Poggio P, Olmi S, Ciccarese F. , et al; Italian Liver Cancer (ITA.LI.CA) Group. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014; 12 (11) 1927-33.e2
    CrossrefPubMedGoogle Scholar
  • 132 Gopal P, Yopp AC, Waljee AK. , et al. Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014; 12 (05) 870-877
    CrossrefPubMedGoogle Scholar